<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - FLURBIPROFEN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>FLURBIPROFEN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#allergyAndCrossSensitivity" data-toggle="tab">Allergy and cross sensitivity</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Pain and inflammation in rheumatic disease and other musculoskeletal disorders</span>,
                <span class="indication">Migraine</span>,
                <span class="indication">Postoperative analgesia</span>,
                <span class="indication">Mild to moderate pain</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                150&#8211;200 mg daily in 2&#8211;4 divided doses, then increased to 300 mg daily, dose to be increased only in acute conditions.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                150&#8211;200 mg daily in 2&#8211;4 divided doses, then increased to 300 mg daily, dose to be increased only in acute conditions.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Dysmenorrhoea</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 100 mg, then 50&#8211;100 mg every 4&#8211;6 hours; maximum 300 mg per day.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 100 mg, then 50&#8211;100 mg every 4&#8211;6 hours; maximum 300 mg per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Relief of sore throat</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using lozenges</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1 lozenge every 3&#8211;6 hours for maximum 3 days, allow lozenge to dissolve slowly in the mouth; maximum 5 lozenges per day.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                1 lozenge every 3&#8211;6 hours for maximum 3 days, allow lozenge to dissolve slowly in the mouth; maximum 5 lozenges per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Inhibition of intra-operative miosis (but does not possess intrinsic mydriatic properties)</span>,
                <span class="indication">Control of anterior segment inflammation following postoperative and post-laser trabeculoplasty when corticosteroids contra-indicated</span>,
            </h4>
            <p class="specificity"><span class="route">To the eye</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                (consult product literature).</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
              <p>Avoid unless the potential benefit outweighs the risk.</p><p>Avoid during the third trimester (risk of closure of fetal ductus arteriosus <i>in utero</i> and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
              <p>Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention.</p><p>Avoid in severe liver disease.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
              <p>The lowest effective dose should be used for the shortest possible duration.</p>
            </section>
        
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
              <p>Avoid if possible or use with caution.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use</h3>
              <p>Deterioration in renal function has also been reported after topical use.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
              <p>Avoid in severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> stomatitis,
              </p>
              <p>
                <strong>uncommon:</strong> confusion, fatigue, hallucinations, paraesthesia,
              </p>
              <p>
                <strong>rare:</strong> alveolitis, aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible), hepatic damage, interstitial fibrosis associated with NSAIDs can lead to renal failure, pancreatitis, papillary necrosis associated with NSAIDs can lead to renal failure, pulmonary eosinophilia, Stevens-Johnson syndrome, toxic epidermal necrolysis, visual disturbances,
              </p>
              <p>
                <strong>notKnown:</strong> mouth ulcers (move lozenge around mouth), taste disturbance, angioedema, blood disorders, bronchospasm, colitis (induction of or exacerbation of), Crohn&#8217;s disease (induction of or exacerbation of), depression, diarrhoea, dizziness, drowsiness, fluid retention (rarely precipitating congestive heart failure), gastro-intestinal bleeding, gastro-intestinal discomfort, gastro-intestinal disturbances, gastro-intestinal ulceration, haematuria, headache, hearing disturbances, hypersensitivity reactions, insomnia, nausea, nervousness, photosensitivity, raised blood pressure, rashes, renal failure (especially in patients with pre-existing renal impairment), tinnitus, vertigo,
              </p>
        
            <section class="advice">
                <h3>Serious side-effects</h3>
              <p>For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see <xref format="dita" href="#PHP78612" type="bookmark" namespace="/treatment-summaries/non-steroidal-anti-inflammatory-drugs">Non-steroidal anti-inflammatory drugs</xref>.</p>
            </section>
        
      </section>





      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>With systemic use:</strong>
            allergic disorders
          </li>
          <li>
              <strong>With systemic use:</strong>
            cardiac impairment (NSAIDs may impair renal function)
          </li>
          <li>
              <strong>With systemic use:</strong>
            cerebrovascular disease
          </li>
          <li>
              <strong>With systemic use:</strong>
            coagulation defects
          </li>
          <li>
              <strong>With systemic use:</strong>
            connective-tissue disorders
          </li>
          <li>
              <strong>With systemic use:</strong>
            Crohn&#8217;s disease (may be exacerbated)
          </li>
          <li>
              <strong>With systemic use:</strong>
            elderly (risk of serious side-effects and fatalities) in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            heart failure
          </li>
          <li>
              <strong>With systemic use:</strong>
            ischaemic heart disease
          </li>
          <li>
              <strong>With systemic use:</strong>
            peripheral arterial disease
          </li>
          <li>
              <strong>With systemic use:</strong>
            risk factors for cardiovascular events
          </li>
          <li>
              <strong>With systemic use:</strong>
            ulcerative colitis (may be exacerbated)
          </li>
          <li>
              <strong>With systemic use:</strong>
            uncontrolled hypertension
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use in adults</h3>
              <p>Caution&#8212;long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.</p>
            </section>
      </section>


      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">When used by <ph outputclass="route">eye</ph> in children</h3>
              <p>Not licensed for use in children.</p>
            </section>
      </section>









      <section class="tab-pane" id="allergyAndCrossSensitivity">
        <h2>Advice regarding allergies and cross sensitivities</h2>

            <section class="contraindications">
              <p>Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID&#8212;which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of FLURBIPROFEN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP77451"><a href="../medicinalForm/PHP77451.html" data-target="#PHP77451" data-action="load">Tablet</a></div>
            <div id="PHP77457"><a href="../medicinalForm/PHP77457.html" data-target="#PHP77457" data-action="load">Lozenge</a></div>
            <div id="PHP77463"><a href="../medicinalForm/PHP77463.html" data-target="#PHP77463" data-action="load">Eye drops</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
